Literature DB >> 33594731

Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.

P Marcant1, P Balayé2, R Merhi3, F Jendoubi4, A Nosbaum5, N Raison-Peyron6, A Du-Thanh6, A Lasek7, M-C Ferrier le Bouedec8, F Tetart9, A Valois10, S Barbarot11, A Soria12, M Jachiet13, D Staumont-Sallé1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33594731     DOI： 10.1111/jdv.17177

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results.

Authors:  Alessandro Vinciguerra; Andrea Rampi; Mona-Rita Yacoub; Moreno Tresoldi; Umberto Tanzini; Mario Bussi; Matteo Trimarchi
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-21       Impact factor: 3.236

2.  Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients.

Authors:  Tiago Torres; Margarida Gonçalo; Maria João Paiva Lopes; Cristina Claro; Leonor Ramos; Manuela Selores; Pedro Mendes Bastos; Joana Rocha; Rodrigo Carvalho; Alberto Mota; Paulo Filipe
Journal:  Drugs Context       Date:  2021-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.